J&J: Large-Scale M&A Still On The Table Despite $10bn Share Buyback
This article was originally published in Scrip
You may also be interested in...
Pfizer's biosimilar franchise is well on its way to becoming a blockbuster business three years after the company launched its first US biosimilar.
The partners have filed the first-in-class NGF inhibitor at the lower 2.5mg dose for the treatment of osteoarthritis pain, despite the drug’s challenging safety profile.
AveXis President David Lennon talked to Pink Sheet about quality enhancement at the gene therapy unit, a clinical trial hold for Zolgensma in Type 2 SMA, and expansion in gene therapy.